INVESTOR RELATIONS
TFA Therapeutics, Inc. is a Cayman Islands exempted company and an SEC-reporting foreign private issuer. Its ordinary shares are quoted on the OTCQB Venture Market under the symbol RAJAF.
TFA AT A GLANCE
Start with the company, lead program, active risk-reduction work and public-market structure, then verify details through filings and evidence pages.
TFA is building an Antcin A-centered development capability spanning controlled source material, purification and analytics, quality standards, evidence generation and cross-market regulatory planning.
Investigational and not approved for marketing.
Completing a milestone reduces a defined risk; it does not equal product approval.
An SEC-reporting foreign private issuer, with annual audits by a PCAOB-registered firm since 2020.
Risk note: TFA-01 safety, efficacy, regulatory acceptability, approval and commercial outcomes have not been established.
VALUE-BUILDING MILESTONES
Published studies support GR/GRα-related signaling for Antcin A in defined models. TFA-01 test-article, batch and indication bridging remains underway.
Next milestoneComplete candidate test-article and batch definition and strengthen program-level pharmacology relevant to canine osteoarthritis.View progress detailsResearch across dozens of strains and content profiles is being connected to controlled cultivation, source selection, purification, analytics and formulation development.
Next milestoneComplete physicochemical validation of the nano-enabled clear aqueous formulation, then advance formal specifications, batch consistency and process scale-up.View progress detailsA 14-day preliminary toxicology study in female rats is complete and a report is available to inform later study design. Target-animal safety, toxicology and residue work continues.
Next milestoneComplete subsequent formal regulatory toxicology reports and establish a program-specific safety range for the purified candidate drug substance and final product.View progress detailsThe Shanghai Pet GCP Clinical Trial Team completed a two-week exploratory observation in 15 dogs. It can inform later protocol design but does not establish efficacy.
Next milestoneComplete a standardized canine osteoarthritis study with a full protocol, prespecified endpoints and a statistical analysis plan.View progress detailsTaiwan veterinary-drug data integration continues while the U.S. CVM path is being planned. Partnership and licensing evaluation will follow the maturity of the evidence.
Next milestoneObtain clear regulatory feedback on study design, process specifications and remaining data gaps, then form an executable submission plan.View progress detailsCOMPANY PROFILE
FILINGS & MARKET INFORMATION
View Form 20-F, Form 6-K and other official documents.
OTCQBView the Company page on OTC Markets.
6-K · JUL 2026View the formal filing for TFA Therapeutics, Inc.
6-K · JUN 2026View the cooperation agreement and platform positioning.
DISCLOSURE PRINCIPLES
Material company information is governed by formal SEC and OTC Markets disclosures.
Progress is communicated through R&D, regulatory, CMC and partnership milestones.
Published research, company-reported preliminary data and forward-looking goals are distinguished.
For public company information, partnership discussions or investor communication, contact the TFA team.
Contact investor relations